New funds will support ongoing commercial activities in Europe, the U.S and Asia and further enhance the development of a next-generation single-cell cloning platform.
Coriolis Pharma, a global service provider and a world leader in the formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, today announced an investment from funds managed by KKR.